Business Context and Reporting Period
This Form 8-K is filed by PerkinElmer, Inc. (noted as REVVITY, INC. in metadata) for the reporting date of October 20, 2011. The filing addresses Item 8.01 (Other Events) regarding the regulatory status of a previously announced acquisition.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone rather than financial performance data.
Material Changes
- Acquisition Clearance: On October 20, 2011, the Company announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- International Approval: The Company received clearance under Germany's Act against Restraints of Competition.
- Target: These clearances relate to the acquisition of Caliper Life Sciences, Inc.
Guidance, Outlook, and Risks
The filing includes a "Safe Harbor" statement regarding forward-looking statements, noting that estimates for future earnings, cash flow, and revenue growth are based on current assumptions. Management highlighted significant risk factors that could cause actual results to differ materially, including:
- Market decline or slower-than-anticipated growth.
- Global economic and political fluctuations.
- Challenges in executing acquisitions, integrating businesses, or achieving profitability from new ventures.
- Intellectual property protection and regulatory compliance issues.
- Supply chain disruptions and raw material availability.
Investor Verification Checklist
- Verify the final closing date and terms of the Caliper Life Sciences, Inc. acquisition.
- Review the attached Press Release (Exhibit 99.1) for specific details on the transaction structure.
- Monitor subsequent filings for the financial impact of the acquisition on PerkinElmer's consolidated results.
- Assess the integration timeline and potential synergies as outlined in management's future communications.